Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma

NCT ID: NCT00064389

Last Updated: 2012-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

746 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-01-31

Study Completion Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety of levalbuterol as compared to racemic albuterol based on the frequencies of adverse events reporting during a 12-month period of chronic dosing of adolescent and adult subjects with asthma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a randomized, open-label, active controlled, multicenter, parallel-group safety study in subjects 12 years of age and older with asthma. Subjects of appropriate age who completed the Phase III levalbuterol HFA MDI trials (Studies 051-353 or 051-355) were eligible to participate. Studies 051-353 and 051-355, both entitled "An Efficacy and Safety Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older with Asthma" were multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group studies of up to nine weeks in duration (a one-week single-blind placebo run in period followed by an eight-week double-blind treatment period). Subjects who completed Studies 051 353 and 051 355 but who were not immediately eligible to rollover into the current study could also participate but only after a 30-day washout. New subjects and subjects who participated in the Phase III trials who were not immediately eligible (ie, had a \>30-day washout) were considered to be de novo subjects.Study participation included 10 study visits over a 12 month period.

This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

levalbuterol 90 mcg MDI QID

Group Type EXPERIMENTAL

levalbuterol tartrate HFA MDI

Intervention Type DRUG

levalbuterol MDI 90 mcg QID

2

racemic albuterol HFA MDI 180 mcg QID

Group Type ACTIVE_COMPARATOR

racemic albuterol

Intervention Type DRUG

racemic albuterol HFA MDI 180 mcg QID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

levalbuterol tartrate HFA MDI

levalbuterol MDI 90 mcg QID

Intervention Type DRUG

racemic albuterol

racemic albuterol HFA MDI 180 mcg QID

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xopenex HFA MDI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to comply with study procedures and visit schedules
* Females 12-60 yrs must have a negative serum pregnancy test at study start
* Women of child bearing potential must use acceptable method of birth control throughout study
* Confirmed diagnosis of asthma minimum of 6 mos. prior to study start
* Have stable baseline asthma and have been using B-adrenergic agonist, and/or anti-asthma anti-inflammatory meds, and/or OTC asthma meds. \>6 mos. prior to study start
* In good health with exception of reversible airways disease and not suffering from any chronic condition that might affect their respiratory function
* Had chest X-ray w/in 12 mos. prior to randomization that is not diagnostic of pneumonia, atelectasis, pulmonary fibrotic disease, pneumothorax, chronic obstructive pulmonary disease etc.
* Subject rolling over from either Sepracor study 051-353 or 051-355 must have successfully completed the study
* Subject who is not immediately rolled over from Sepracor study 051-353 or 051-355 must wait \>30 days and will be regarded as a de novo subject
* Able to complete daily diary cards and medical event calendars reliably, understand dosing instructions, demonstrate how to use the MiniWright PEF meter. Minor subjects must have a parent/legal guardian assist them during the study with these activities

Exclusion Criteria

* Female who is pregnant or lactating
* Participated in investigational drug study w/in 30 days prior to study start, or currently participating in another clinical trial, other than Sepracor studies 051-353 or 051-355
* Subject who early terminated from Sepracor study 051-353 or 051-355
* Subject whose schedule prevents him or her from taking the first daily dose of study medication and/or starting study visits before 10 AM
* Have travel commitments during the study that would interfere with trial measurements and/or compliance
* History of hospitalization for asthma w/in 45 days prior to study start, or scheduled for in-patient hospitalization, including elective surgery during the trial
* Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations
* Subject using any prescription drug with which albuterol sulfate is contraindicated
* Subject with currently diagnosed life-threatening asthma
* History of cancer (exception: basal cell carcinoma in remission)
* Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or may interfere with the successful completion of this protocol
* History of substance abuse or drug abuse within 12 months preceding V1
* Subject with \>10 pack/yr history of cigarette smoking or use of any tobacco products within 6 months of study start
* Documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis
* Have suffered from a clinically significant upper or lower respiratory tract infection in the 2 weeks prior to study start
* Subject who is a staff member or relative of a staff member
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sumitomo Pharma America, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jefferson Clinic PC

Birmington, Alabama, United States

Site Status

Pulmonary Associates Research Division

Mobile, Alabama, United States

Site Status

Montgomery Pulmonary Consultants

Montgomery, Alabama, United States

Site Status

Center of Research Excellence, LLC

Oxford, Alabama, United States

Site Status

Lovelace Scientific Resources

Phoenix, Arizona, United States

Site Status

Alta Clinical Research, LLC

Tucson, Arizona, United States

Site Status

Integrated Research Group

Corona, California, United States

Site Status

Northern California Research Corp

Fair Oaks, California, United States

Site Status

Allergy, Asthma & Respiratory Care Center

Long Beach, California, United States

Site Status

Madera Family Medical Group

Madera, California, United States

Site Status

Clinical Trials of Orange County, Inc.

Orange, California, United States

Site Status

Institute of Healthcare Assessment, Inc.

San Diego, California, United States

Site Status

Westlake Medical Research, Inc.

Westlake Village, California, United States

Site Status

Office of Constantine Falliers, MD

Denver, Colorado, United States

Site Status

Office of Gary Richmond, MD

Fort Lauderdale, Florida, United States

Site Status

CNS Clinical Trials

Fort Myers, Florida, United States

Site Status

FPA Clinical Research

Kissimmee, Florida, United States

Site Status

Orlando Clinic for Asthma & Respiratory Diseases

Longwood, Florida, United States

Site Status

Allergy Sinus Asthma Research Institute

Miami, Florida, United States

Site Status

Florida Center for Alergy & Asthma Research

Miami, Florida, United States

Site Status

Orlando Clinical Research Center

Orlando, Florida, United States

Site Status

Family Allergy & Asthma Center, PC

Atlanta, Georgia, United States

Site Status

The Allergy & Asthma Clinic Research Center

Conyers, Georgia, United States

Site Status

Aeroallergy Research

Savannah, Georgia, United States

Site Status

Sneeze, Wheeze and Itch, LLC

Bloomington, Illinois, United States

Site Status

Rush Presbyterian - St. Luke's Medical Center

Chicago, Illinois, United States

Site Status

Children's Asthma Respiratory & Exercise Specialists

Glenview, Illinois, United States

Site Status

Cardinal Respiratory, PC

Springfield, Illinois, United States

Site Status

Clinical Research Center of Indiana

Indianapolis, Indiana, United States

Site Status

South Bend Clinic

South Bend, Indiana, United States

Site Status

Consultants in Pulmonary Medicine

Olathe, Kansas, United States

Site Status

Heartland Research Associates

Wichita, Kansas, United States

Site Status

Northshore Medical Research

Covington, Louisiana, United States

Site Status

Institute for Asthma & Allergy, PC

Wheaton, Maryland, United States

Site Status

Center for Clinical Research

Taunton, Massachusetts, United States

Site Status

Henry Ford Hospital & Medical Centers

Detroit, Michigan, United States

Site Status

Hurley Child and Adolescent Asthma Center

Flint, Michigan, United States

Site Status

Clinical Research Institute

Minneapolis, Minnesota, United States

Site Status

Allergy, Asthma, Immunology Services, LLC

Jefferson City, Missouri, United States

Site Status

Midwest Chest Consultants, PC

Saint Charles, Missouri, United States

Site Status

Washington University School of Medicine, Division of Allergy & Immunology

St Louis, Missouri, United States

Site Status

Montana Medical Research, LLC

Missoula, Montana, United States

Site Status

Allergy, Asthma & Immunology Associates, PC

Lincoln, Nebraska, United States

Site Status

Heartland Clinical Research Inc.

Omaha, Nebraska, United States

Site Status

Office of Meera Dewan, MD

Omaha, Nebraska, United States

Site Status

Delaware Valley Institute for Clinical Research

Cherry Hill, New Jersey, United States

Site Status

Clinical Research Center of Allergy & Asthma Consultants

Tinton Falls, New Jersey, United States

Site Status

Lovelace Scientific Resources

Albuquerque, New Mexico, United States

Site Status

Allergy & Asthma of Northern NM

Los Alamos, New Mexico, United States

Site Status

Pulmonary Medical Research of NY

Bay Shore, New York, United States

Site Status

Asthma & Allergy Associates, PC

Cortland, New York, United States

Site Status

Office of Michael Marcus, MD

Staten Island, New York, United States

Site Status

Office of Richard Castaldo

Tonawanda, New York, United States

Site Status

Regional Allergy & Asthma Consultants

Asheville, North Carolina, United States

Site Status

Charlotte Lung & Health Center

Charlotte, North Carolina, United States

Site Status

Neem Research Group, Inc.

Charlotte, North Carolina, United States

Site Status

Cornerstone Research Care

High Point, North Carolina, United States

Site Status

Carolina MedTrials, LLC

Winston-Salem, North Carolina, United States

Site Status

Allergy & Asthma Care Center

Fargo, North Dakota, United States

Site Status

Sterling Research Group

Cincinnati, Ohio, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

Optimed Research LLC

Columbus, Ohio, United States

Site Status

Allergy, Asthma & Clinical Research Center

Oklahoma City, Oklahoma, United States

Site Status

Allergy, Asthma and Dermatology Research Center

Lake Oswego, Oregon, United States

Site Status

Medford Medical Clinic, LLP

Medford, Oregon, United States

Site Status

Bellevue Pediatric Associates

Bellevue, Pennsylvania, United States

Site Status

Valley Clinical Research Center

Easton, Pennsylvania, United States

Site Status

Allergy & Asthma Research of NJ, Inc.

Philadelphia, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Advanced Clinical Concepts

Shillington, Pennsylvania, United States

Site Status

Neem Research Group of Charleston

Charleston, South Carolina, United States

Site Status

Neem Research Group Inc.

Columbia, South Carolina, United States

Site Status

Allergic Disease & Asthma Center, PA

Greenville, South Carolina, United States

Site Status

Asthma Institute

Chattanooga, Tennessee, United States

Site Status

The Allergy Associates

Knoxville, Tennessee, United States

Site Status

Office of Constantine Saadeh

Amarillo, Texas, United States

Site Status

Allergy & Asthma Clinical of Central Texas

Austin, Texas, United States

Site Status

UTX Medical

Galveston, Texas, United States

Site Status

Breco Research

Houston, Texas, United States

Site Status

Breath of Life Research Institute

Houston, Texas, United States

Site Status

Clinical Trials of North Houston

Houston, Texas, United States

Site Status

Central Texas Health Research

New Braunfels, Texas, United States

Site Status

Lung Diagnostics

San Antonio, Texas, United States

Site Status

Hampton Roads Center for Clinical Research

Norfolk, Virginia, United States

Site Status

Pulmonary Associates of Richmond Inc.

Richmond, Virginia, United States

Site Status

Virginia Adult & Pediatric Allergy & Asthma PC

Richmond, Virginia, United States

Site Status

National Clinical Research

Richmond, Virginia, United States

Site Status

The Physician's Clinic of Spokane

Spokane, Washington, United States

Site Status

Allergy, Asthma, and Sinus Center F.C.

Greenfield, Wisconsin, United States

Site Status

Milwaukee Medical Clinic

Milwaukee, Wisconsin, United States

Site Status

Allergic Diseases, S.C.

West Allis, Wisconsin, United States

Site Status

Trial Management Group

Vancouver, British Columbia, Canada

Site Status

St. Boniface General Hospital

Winnipeg, Manitoba, Canada

Site Status

Clinical Research Group

Mississauga, Ontario, Canada

Site Status

Niagara Clinical Research, Inc.

Niagara Falls, Ontario, Canada

Site Status

Primary Care Lung Clinic

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

051-356

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.